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Effect of a Single Oral Dose of Milrinone on Left Ventricular Diastolic
Performance in the Failing Human Heart
FEDERICO PISCIONE, MD, BRIAN E. lASKI, MD, GERT 1. WENTING, MD,
PATRICK W. SERRUYS, MD, FACC
Rotterdam, The Netherlands
In 14 patients with severe congestive heart failure, left
ventricular pressure (measured by tip manometer) and
derived variables were measured before and every 10
minutes after administration of oral milrinone (10 mg)
for 50 minutes along with measurements of coronary
sinus blood flow and drug plasma levels. Arterial and
coronary sinus catecholamines were measured only be-
fore and 50 minutes after milrinone. Left ventricular
pressure, volume (as determined by angiography) and
derived indexeswere simultaneouslyassessedat matched
atrial paced heart rate before and 60 minutes after mil-
rinone. Three patients who did not achievea therapeutic
plasma level «150 ng/mt) were excluded.
Peak negative first derivative of left ventricular pres-
sure ( - dP/dt) progressively and significantly increased
(10%) together with a decrease in the two exponential
time constants of relaxation, namely, Tau, (19%) and
Tau, (22%), which represent the fit for and after the
first 40 ms, respectively. Coronary flow significantly in-
Despite therapy with digitalis, diuretic drugs and arterial
and venous vasodilators, patients with congestive heart fail-
ure become progressively unresponsive as the severity of
the disease progresses. Recently, a new class of cardiac
inotropic drugs, the bipyridines, has been tested in animals
and humans and has opened new avenues of treatment. The
forerunner of these new compounds was amrinone. Intra-
venous and oral administration of this drug resulted in sub-
stantial acute hemodynamic improvement in patients with
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creased by 43% within 30 minutes, whereas the decrease
(-13%) in coronary vascular resistance failed to be sta-
tistically significant. No change occurred in catechol-
amine concentrations after milrinone. Peak filling rate
significantlyincreased by 15%. Pressure-volume curves
showed a leftward and, in four patients, a downward
shift; a significant decrease in minimal left ventricular
diastolic and end-diastolic pressures (by 55 and 38%,
respectively) and in end-diastolic volume (18%) oc-
curred. The constant of elastic chamber stiffness mea-
sured by the simple elastic model tended to decrease,
but failed to achieve a statistically significant level.
Thus, oral milrinone improved left ventricular early
relaxation and filling as well as chamber distensibility.
This global improvement of diastolicfunction makes mil-
rinone a potentially useful drug in the oral treatment of
heart failure.
(J Am Coll CardioI1987;lO:1294-302)
congestive heart failure (1-3). However, amrinone therapy
may cause thrombocytopenia, fever or major gastrointestinal
side effects (2,3). As a result, other compounds with similar
chemical structure were investigated, and milrinone has
emerged as the most promising (4). In patients with conges-
tive heart failure, milrinone improves left ventricular ino-
tropic state with a concurrent arteriolar vasodilation as dem-
onstrated after intravenous (5-8) and oral (9) administration.
Because it is conceivable that systolic and diastolic func-
tion and dysfunction are coupled processes, milrinone may
have a major impact on left ventricular relaxation, as re-
cently reported (6). Furthermore an improved diastolic re-
laxation and distensibility might lead to more effective sar-
comere length within the ventricular myocardium and cause
the failing myocardium to operate at a more efficient point
of sarcomere pressure-length relation. Our study evaluates
the effects of a single oral dose of milrinone on multiple
variables of left ventricular diastolic function in patients with
severe congestive heart failure.
0735-1097/87/$3.50
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Methods
Study patients (Table 1). After approval of the study
protocol by the Ethics Committee of Erasmus University
and informed consent were obtained, 14 patients (10 men
and 4 women) entered the study. All patients had severe
congestiveheart failure (New York Heart Association func-
tional class III or IV), despite optimal conventional therapy
with digitalis and diuretic drugs in all patients and nitrates
or angiotensin-converting enzyme inhibitors, or both, in
eight patients. All patients had undergone cardiac catheter-
izationon a separate occasionduring the preceding 2 years,
and the diagnosis of ischemiccardiomyopathy in 12 of them
was based on the presence of severe multivessel coronary
artery disease. One or several previous episodes of myo-
cardial infarction were clinically and electrocardiographi-
cally or enzymatically (or both) documented in 10patients.
In the remaining two patients, the presence of an intraven-
tricular conduction disturbance precluded retrospective de-
tection of a silent myocardial infarction. The remaining two
patients had idiopathic dilated cardiomyopathy. Patients with
symptomatic angina pectoris, myocardial infarction within
3 months or organic valvular heart disease were excluded.
Elevenpatientshad sinusrhythmand threehad chronicatrial
fibrillation.
Study protocol. All vasodilators were withheld24 hours
before the study. Diuretic drugs were withheld 12 hours
before the study, and digoxin was withheld on the morning
of study.
A triple lumen 7F balloon-tipped thermodilution catheter
wasadvancedto the mainpulmonary arteryfromthe femoral
vein. An 8F micromanometer-tipped pigtail catheter was
Table 1. Clinical and Angiographic Characteristics of 14 Patients
advanced to the left ventricle from the right femoral artery,
and a 5F micromanometer-tipped catheter was placed in the
ascending aorta from the left femoral artery to measure the
aortic pressure and withdraw blood samples. A Webster
coronary sinus thermodilution catheter was advanced to the
coronary sinus from a right antecubital vein. The catheter
position was ascertained by initial contrast injection and
subsequent fluoroscopy. Heart rate, right atrial pressure,
cardiacoutput, aortic and left ventricularpressuresand pres-
sure-derived indexes of isovolumic relaxation were then
measured. After a baselinehemodynamic measurement, the
following protocol was started:
1) Left ventricular cineangiography at an atrial paced
heart rate 15 beats higher than spontaneous heart rate was
performed at 50 frames/s in a 30°right anterioroblique view
by injection of nonionic contrast medium (0.7 cc/kg metri-
zamide [AmipaqueJ), which has been shown to have no
hemodynamic effect (10). Care was taken to maintain a
uniform patient position relative to X-ray equipment dur-
ing angiography. which was performedwith the breath held
in shallow inspiration. Simultaneous beat to beat analysis
of left ventricular pressure and its derived indexes was car-
ried out during cineangiography.
2) Fifteen minutes after angiography, baseline hemo-
dynamic measurements were repeated. At the same time,
coronary sinus blood flow was measured and arterial and
coronarysinus blood samples were withdrawn to determine
catecholamine and hypoxanthine concentrations.
3) Milrinone, 10 mg, was given orally.
4) Every 10 minutes for 50 minutes, the measurements
were repeated as in protocol 2. Blood samples for cate-
cholamine and hypoxanthine measurements were withdrawn
Age (yr) Previous EF Angiography Coronary Arteriography (%)
Case &Sex Diagnosis/NYHA MI (%) Hypo Dys Aki LAD LCx RCA
I 49F CMP ischemic/III + 7 AB.PB AL.AB.IB 100 70 90
2 58M CMP ischemic/III 17 AB,IB.PB AP AL 100 90
3 59M CMP ischemic/III + 20 AB.AL.AP !B.PB 90 60 100
4 51M CMP ischemic/III + 39 IB.PB AP AL 90 60
5 65F CMP ischemic/III + 14 IB AP AL 100 50
6 62M CMP ischemic/III + 35 AB.AL,IB.PB AP 90 70
7 53M CMP ischernic/l V + 23 PB AL+IB 90 70
1\ 64M CMP ischemic/III 24 AB.AL,IB.PB AP 100 70 90
9 58M CMP ischemic/III + 1\ AB.PB AL.AP.IB 100 60
10 65F CMP idiopathic/IV II Global
II 53F CMP ischemic/III + 14 AL.1B AP 100 70
12 55M CMP ischemic/III + 16 AL AP.IB.PB 70 50 100
13 68M eMP idiopathic/III 20 Global 50 70
14 71M CMP ischemic/III + 17 AB.AP.IB AL PH 90 100
AB = anterobasal; AL = anterolateral; Aki = akinesia; AP = apical; CMP = cardiomyopathy; Dys = dyskinesia; EF = ejection fraction; F =
female; Hypo = hypokinesia; IE = inferobasal; LAD = left anterior descending artery: LCx = left circumflex artery: LV Angio = left ventricular;
M = Male; MI = myocardial infarction; NYHA = New York Heart Association functional class; PB = posterobasal; RCA = right coronary artery.
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only at 50 minutes. An additional blood sample was with-
drawn every 10 minutes to determine the plasma levels of
milrinone.
5) Left ventricular cineangiography at a matched atrial
paced heart rate with simultaneous beat to beat left ven-
tricular pressure recording was repeated 60 minutes after
the drug administration. In the three patients with atrial
fibrillation, heart cycles of similar length were selected to
compare the sequential left ventricular angiograms.
Analysis of left ventricular pressure-derived indexes.
Left ventricular pressure was digitized at 250 samples/s.
Minimaldiastolic and end-diastolic left ventricular pressures
and its peak negative first derivative ( - dP/dt) were com-
puted on-line after data acquisition for 20 seconds. For off-
line analysis of left ventricular pressure decay, an updated
version of the beat to beat program described previously
(I I) was used with the following definitions: I) pressure at
the beginning of isovolumic relaxation (Pb) is the pressure
at the point at which dP/dt is minimal (maximal negative
dP/dt), and 2) pressure at the end of isovolumetric relaxation
(PJ is the pressure less than or equal to the previous end-
diastolic pressure, but no less than I mm Hg. Although it
is possible that the latter definition may result in Pe being
measured just after mitral valve opening, estimation of the
time constants by more stringent criteria, such as end-dia-
stolic pressure + 10mm Hg, did not result in a significantly
better estimation and failed to measure pressure during high
heart rates (12).
Semilogarithmic model. An off-line isovolumic relax-
ation was carried out using the following semilogarithmic
model: pet) = Poe - tn', where P is pressure and Po is equiv-
alent to P, (pressure at beginning of isovolumic relaxation)
when a true exponential decay is present starting from the
time of peak negative dP/dt; the Po and T variables were
estimated from a linear least-squares fit on In P = - tIT
+ In Po. This technique requires a minimum of eight sam-
ples (over 32 ms) between P, and Pe . In addition, a biex-
ponential fit for isovolumic relaxation was determined, char-
acterized by the two exponential time constants; the fit for
the first 40 ms (n = 8), Tau" and the fit after the first 40
ms, Tau2 (12) .
Mitral valve opening pressure was defined during left
ventriculography as occurring in the last frame preceding
the entry of nonopacified blood into the left ventricle from
the left atrium. The left ventricular pressure corresponding
to this frame was considered to reflect left atrial pressure.
Coronary blood flow measurements. In 13 patients,
coronary sinus flow was measured by the continuous ther-
modilution method of Ganz et al. (13) . Coronary vascular
resistance was derived from the ratio of mean aortic pressure
to coronary sinus blood flow.
Analysis of left ventricular diastolic volume and de-
rived variables. A complete cardiac cycle was analyzed
on a frame to frame basis from each angiogram. The ven-
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Table3. Left Ventricular Diastolic Performance at Matched
Paced Heart Rate Before and 60 Minutes After Oral Milrinone
in II Patients
of milrinone is approximately 150ng/ml, we excluded from
analysis the three patients with a lower level. One of these
three patients had idiopathic dilated cardiomyopathy.
Measurements during short-term monitoring of mil-
rinone effect (Table 2). The heart rate did not change
during the study period, and mean aortic pressure decreased
slightly but signifi cantly after 50 minutes. Changes observed
in right atrial pressure, cardiac output and systemic vascular
resistance are reported in Table 2. Both peak positive dP/dt
and peak negative dP/dt increased over the study period,
reaching a peak value after 50 minutes. The time constants
of left ventricular relaxation (Tau I , which represents the fi t
for the first 40 ms, and Tau-, which represents the fit after
40 ms) showed similar improvement. The minimal and end-
diastolic left ventricularpressures both decreasedduring the
monitoring period.
Coronary blood flow increased progressively during the
first 40 minutes , when it reached its peak value and then
decreased slightly during the remaining IO minutes. Con-
comitantly, coronary vascular resistance showed minimal
and insignificant changes during the study. The myocardial
arteriovenous difference of hypoxanthine was 0.27 ± 0.64
fLmolll iter before milrinone and, on average, did not change
50 minutes after drug administration (0.81 ± 1.4 j..tmolJliter).
In two patients (Cases 2 and 4), a negative myocardial
arteriovenous difference of hypoxanthine detected in the
basal state had subsided by the end of the study. In one
Before Milrinone After Milrinone
tricular contours were detected using an automated hard-
wired system (14) and the volumes, calculated according to
Simpson's rule, were graphically displayed as instantaneous
volume and its derivative (d v /dt) , In this way, end-diastolic
and end-systolic volumes, total cardiac index, stroke index
and ejection fraction were obtained. Peak filling rate was
defined as the greatest volume inflow rate (dV/dt) occurring
early after end-systole. The simultaneous recording of pres-
sure and volumeduring left ventricular angiography allowed
us to obtain a pressure-volume curve before and after drug
administration in every patient. For the evaluation of global
chamber stiffness, the left ventricular pressure (P) and vol-
ume (V) data obtained every 20 ms, starting at the lowest
diastolic pressure and ending at the end-diastolic pressure,
were fitted by a simple elastic model: P = ae{3Y + C,
where a = intercept (mm Hg), {3 = constant of elastic
chamber stiffness and C = asymptote (mm Hg). The three
constants of this equation a, (3 , C were determined using
an iteration procedure until the best nonlinear curve fi t was
obtained (15).
Metabolic measurements. Plasma levels of milrinone
were measured using a validated high performance liquid
chromatography procedure (16). An isocratic pressure liquid
chromatographic system was used for estimation of hypo-
xanthine concentrations in blood ( 17) .
Plasma levels of norepinephrine , epinephrine and do-
pamine were measured in duplicate, both with and without
internal standards by the radioenzymatic procedure of Peuler
and Johnson (18) with slight modifications. Normal basal
values in our laboratory are 100 to 500 pg/ml for norepi-
nephrine and 10 to 110 pg/ml for both epinephrine and
dopamine. Assuming that epinephrine and norepinephrine
are removed similarly by the heart, the amount of sympa-
thetically mediated norepinephrine release (net myocardial
norepinephrine flux) can be estimated by the following for-
mula: (coronary sinus - aorta) norepinephrine x coronary
sinus blood flow x (1 - hematocrit), where coronarysinus
levels are corrected for the amount of norepinephrine ex-
tracted by the heart.
Statistical analysis. Results during hemodynamic mon-
itoring are given as mean :±: standard deviation. Analysis
of variance for repeated measurements was used for statis-
tical analysis of the data followed by a multiple comparison
test, according to methods of Dunnett (19) and Tukey (20).
Statistical analysis of measurements during angiography and
of catecholamine and hypoxanthine levels was performed
using Student's t test for paired data.
RR (rns)
ESP (mm Hg)
ESVI (ml/m')
ESP/ESV[ (mm Hg/ml per rrr')
Peak positive dP/dt (mm Hg/s)
Peak negative dP/dt (mm Hgls)
Tau I (ms)
Tau, (rns)
MVO (mm Hg)
PFR (mIls)
Pmin (rum Hg)
LVEDP (mm Hg)
EDVI (ml/m' )
RA (mm Hg)
TSG (rnrn Hg)
a (rnrn Hg)
{3
C (mm Hg)
6 13 ::t 122
7 1 ::t 20
148 ::t 64
60 :t 45
1,0[4 ::t 365
836 ::t 230
67 :t 17
58 ::t 17
27 :t 12
282 :!: 96
20 :!: 6
3 1 ::t 10
178 ::t 63
8 :t 5
22 :!: 9
2.3 ::t 3.3
0 .026 :t 0.0 1
- 5.8 :!: 12
620 ± 147
63 ± 16
130 ± 64t
63 ± 40
1,164 ± 388t
959 ± 326*
57 ± 19*
45 ± 17*
22±1O
325 ± 112t
'J ± 6*
19 ± 11*
164 ± 68t
4 ± 4*
15 ± 8t
1.1 ± 1.4
0 .020 :!: 0 .008
- 3.3 ± 9
Results
Measurements of the plasma level of milrinone 50 min-
utes after drug intake showed that of 14 patients. only II
had a plasma level > 150 ng/ml . Because it has been pre-
viously demonstrated (21) that the therapeutic plasma level
*p < 0 .00 1(compared with before milrinone): t p< 0.05. a = pressure
intercept; {3 = constant of elasticchamber stiffness; C == asymptote; EDVI
= end-diastolic volume index; ESP == end-systolic left ventricular pres-
sure; ESVI = end-systolic volume index; MVO = pressure at mitral valve
opening; PFR = peak filling rate; Pmin = minimal left ventricular diastolic
pressure; RR = cycle length; TSG = transseptal gradient (LVEDP -
RA); other abbreviations as in Table 2.
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patient (Case 8), a negative balance in myocardial hypo-
xanthine was observed after milrinone. Nevertheless, none
of these patients had clinical or electrocardiographic signs
of ischemia and their hemodynamic measurements did not
differ from those recorded in the remaining patients.
Measurements during left ventricular angiography
(Table 3). End-systolic pressure measured at the occurrence
of the dicrotic notch on the aortic pressure tracing did not
change, whereas end-systolic volume decreased slightly but
significantly (p < 0.05). The analysis of isovolumic relax-
ation before and after milrinone showed a significant (p <
0.01) increase in peak negative dP/dt with a concomitant
significant decrease in the biexponential time constants of
relaxation, Tau] (p < 0.0l) and Tauz (p < 0.0l). The
pressure at mitral valve opening, a measure of left atrial
driving pressure, increased in four patients, decreased in
five patients and showed no change intwo patients after
milrinone. A significant (p < 0.05) increase in peak filling
rate occurred. Left ventricular minimal diastolic pressure,
end-diastolic pressure and end-diastolic volume decreased
significantly (p :::; 0.05). The right atrial pressure and the
difference between left and right ventricular filling pressures
(transseptal gradient), measured as an estimate of average
diastolic force gradient across the interventricular septum,
also decreased significantly. In most of the patients, analysis
of pressure-volume loops showed a leftward shift after mil-
rinone with a downward shift in four patients (Fig. 1). In
this subset of patients, a substantial reduction in pressure
throughout a range of volumes common to both pre- and
postmilrinone functions reflected a major change in right
atrial pressure.
The constant of elastic chamber stiffness, the intercept
and the asymptote, failed to show significant changes.
Nevertheless, as shown in Figure 2, a dramatic improvement
in the slope of the pressure-volume curve was observed in
some patients after milrinone, and it is conceivable that if
a different dose of milrinone had been used for those patients
Figure 1. Individual pressure-volume curves in II patients before
(dotted line) and 60 minutes after (solid line) administration of
oral milrinone. The concomitant decrease in end-diastolic pressure
and volume caused a leftward shift of the curve in most of the
patients. In four patients an evident downward shift was observed,
indicating improved left ventricular chamber distensibility; in these
four patients, a major decrease in right atrial pressure, demon-
strating a reduction in pericardial constraint, occurred.
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who are at variance with the means observed, our findings
would have been more uniform.
Plasma catecholamines. Data suitable for analysis were
obtained in 10 patients. As could be expected in these pa-
tients with severe heart failure, arterial norepinephrine was
markedly elevated in nearly all patients, but in the majority
of them arterial epinephrine and dopamine levels were also
in excess of the normal range (Fig. 3). Over the coronary
vascular bed, extraction of epinephrine occurred, the mean
uptake by the heart being 31 ± 6% (the cardiac venoarterial
difference as a percent of arterial levels). In contrast, nor-
epinephrine levels were higher in the coronary sinus than
in the aorta, the venoarterial difference being 60 ± 18%.
No clear venoarterial difference over the heart was found
for dopamine. Milrinone had no effect on the arterial and
coronary sinus plasmalevels of norepinephrine, epinephrine
or dopamine, and sympathetic drive to the heart as estimated
Figure 2. Individual and groupmeanchanges inconstantofelastic
chamber stiffness after milrinone administration in 11 patients
(right panel). A definite decrease was observed in only a few
patients. In the left panel, an example of the beneficial change in
the slopeofthe pressure-volumecurve, demonstrating an improved
elastic chamber stiffness after milrinone (e), is shown. (l' = in-
tercept (mm Hg); f3 = constant of elastic chamber stiffness;c =
asymptote (mm Hg).
by the net myocardial norepinephrine flux also was not
altered by the drug. Before milrinone, it was 43,435 ±
13.010 pg/rnin; after milrinone, it was 49,465 ± 12,559
pgtmin.
Discussion
The diastolic properties of the left ventricle are important
determinants of cardiac function. Delayed left ventricular
relaxation. loss of elastic recoil, changes in chamber stiff-
ness, changes in right ventricular loading conditions, effects
of pericardium and coronary perfusion and changes in left
ventricular shape all may contribute to abnormal diastolic
function and the clinical manifestations of congestive heart
failure (22). In this study, we evaluated the effect of mil-
rinone on these multiple determinants of left ventricular
diastolic function.
Improvement in relaxation and diastolic filling after
milrinone: a direct or catecholamine-mediated phenom-
enon? Before milrinone, the time constants of relaxation
in our patients were severely prolonged. Within 30 minutes
after oral administration. milrinone consistently improved
these variables. Since the two major hemodynamic deter-
minants of left ventricular relaxation rate (end-systolic pres-
sure and heart rate) did not change after administration of
milrinone, it seems reasonable to conclude that relaxation
.045
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was improved because of a direct effect of the drug on the
failing myocardium.
In the mammalian heart, catecholamines can exert a sub-
stantial myocardial relaxing effect by stimulating the cal-
cium uptake by sarcoplasmic reticulum (23). Therefore,
Monrad et al. (6) have suggested that the effects of intra-
venous milrinone on myocardial relaxation could be due to
a drug-induced release of endogenous catecholamines.
However, no data were provided to validate their hypoth-
esis. In the present study, the plasma levels of norepineph-
rine, epinephrine and dopamine in both the aorta and the
coronary sinus did not change after milrinone. In addition,
we measured the net myocardial norepinephrine flux to es-
timate a release, if any, of sympathetically mediated nor-
epinephrine from the heart. The lack of change in this vari-
able after milrinone intake makes it unlikely that changes
in sympathetic tone played an important role in the effect
of milrinone on relaxation rate.
In the failing heart, the sarcoplasmic reticulum, which
plays an essential role in the active relaxation of myocar-
dium, accumulates less calcium and binds and releases cal-
cium at slower rates than it does in a normal heart (24).
Milrinone has been proved to act as a phosphodiesterase
inhibitor, causing an increase in intracellular cyclic aden-
osine monophosphate (AMP), which results in improved
uptake, storage and release of calcium by the sarcoplasmic
reticulumduring excitation-contractioncoupling (25). Thus,
it seems conceivable to attribute the improvement in relax-
ation rate to a direct effect of milrinone on the fiber cell.
Ishida et al. (26) recently demonstrated that under con-
ditions of similar left atrial pressure at mitral valve opening,
the rate of relaxation influences the rate, amplitude and
duration of early filling, whereas under conditions of similar
left ventricular pressure decay, the left atrial pressure influ-
ences the early filling. Instead of this pressure, we used
mitral valve opening pressure as an alternative to the left
atrial driving pressure. In 7 of the II patients with thera-
peutic plasma levels after milrinone administration, we ob-
served no changes in the mitral opening pressure, suggesting
Figure 3. Levels of plasma norepinephrine, epinephrine and do-
pamine measured simultaneously in the aorta and coronary sinus
in 10patients. Note thatin most patients values fornorepinephrine
levels were higher in the coronary sinus than in the aorta. The
opposite was found for epinephrine. The open circles indicate
values before milrinone; the closed circles indicate values after
milrinone. The normal area is also indicated. Milrinone had no
effect on the plasma levels of norepinephrine in the aorta (before
708 ± 388 pg/ml; after 690 ± 611 pg/rnl) and coronary sinus
(before 1,047 ± 611 pg/ml; after I.038 ± 552pg/ml). Epineph-
rine and dopamine levels in the aorta and coronary sinus after
milrinone also did not change.
that the observed increase in peak filling rate in these 7
patients was due to the improved relaxation rate.
Diastolic pressure-volume relation. The decrease in
left ventricular minimal and end-diastolic pressures together
with a decrease in end-diastolic volume caused a leftward
and, in some cases, downward shift in left ventricular pres-
sure-volume curves. These shifts might stem either from
alteration of chamber stiffness or from changes in extra-
cardiac conditions.
It has been postulated (27) that both the pericardium and
the right ventricle are important determinants of left ven-
tricular distensibility, and a rapid shift toward normal of the
diastolic pressure-volume relation observed in congestive
heart failure after vasodilating or inotropic drugs may be
related to relief of extrinsic compression of the distended
left ventricle by the pericardium and right ventricle (28,29).
Recently, Tyberg et al. (29) demonstrated that right atrial
pressure accurately reflects intrapericardial pressure over a
wide pressure range and, because of this close relation,
provides a reliable estimate of true left ventricular preload.
Thus, in our patients, the decrease in right atrial pressure.
which likely reflects a reduction in pericardial constraint,
might have contributed to the downward shift in the pres-
sure-volume curves observed in some of them.
It has been reported (30) that a major change in coronary
perfusion pressure, or flow influencesthe wall thickness and
chamber stiffness through an engorgement of the wall (the
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so-called erectile or hydraulic effect). Because this effect is
greater when the ventricle is stiffer, changes in coronary
pressure or flow occurring in patients with volume overload
would more severely affect left ventricular diastolic com-
pliance (28).
After rnilrinone, we observed an increase in coronary
blood flow with a minor change in perfusion pressure so
that impaired compliance with an increased stiffness due to
an erectile effect might have occurred. Although an increase
in blood flow might not necessarily be equated with an
increase incoronaryvascular volume, the actual determinant
of the erectile effect (30) (the coronary vasodilation ob-
served after milrinone) might have resulted in a vascular
engorgement of the myocardial wall. This latter phenom-
enon could have affected the pressure-volume relation un-
favorably and might have masked a beneficial intrinsic de-
crease in diastolic myocardial tone.
Chamber stiffness increases in patients with congestive
cardiomyopathy, probably because of an increased amount
of fibrous tissue within the myocardium (1 5,22). To char-
acterize the intrinsicdiastolic properties of myocardial wall,
a viscoelastic rather than a simple elastic stress-strain re-
lation (31) should be used. Our angiographic data do not
allow us to quantitate properly strain rates that are essential
for determining diastolic viscous effects. Regional wall
thickness measurements are needed to characterize the change
in myocardial stiffness, but such data cannot be measured
accurately at 20 ms intervals from the left ventricular an-
giogram. As a result of the use of the single elastic model.
the constant of stiffness we calculated includes both elastic
and viscous forces. Despite these limitations, the highvalues
we observed in diastolic chamber stiffness in the failing
heart arc in accordance withprevious observations (15,22,31) .
After milrinone, a trend to improvement was observed, al-
though it was not statistically significant.
Observations ori pharmacokinetics and potential lim-
itations of the study. In any study where a drug is eval-
uated, many factors such as dose-response characteristics,
pharmacokinetics and concomitant drug administration need
to be considered. A previous study (32) demonstrated that
2.5 and 5 mg doses of oral milrinone have minimal hemo-
dynamic effect when administered to patients with severe
congestive heart failure and they should be considered sub-
therapeutic. In the same study (32), patients treated with
7.5 and.10 mg doses showed significant hemodynamic im-
provement without the adverse hemodynamic effects ob-
served with the 15 mg dose. These observations suggest
that 10 mg is the optimal dose.
After oral administration of a drug. there are individual
differences in the rate of gastrointestinal absorption as well
as the renal and hepatic perfusion rates that could influence
the therapeuticplasma levels. It has been demonstrated (33)
that the half-life and clearance of oral milrinone are signif-
icantly prolonged in patients with heart failure as compared
with values in normal volunteers. Therefore, the variations
observed in the improvement of left ventricular diastolic
function and central hemodynamics could simply reflect
differences in individual clinical status. We observed a pla-
teau in the hemodynamic response to milrinone during the
last 20 minutes of the study. This could be explained by
the action of milrinone on phosphodiesterase, which does
not continue to increase once maximal inhibition is reached,
thereby limiting the hemodynamic improvement (34).
An important question is whether the optimal patient
population and protocol design were used. The large ma-
jority of the patients entered were in New York Heart As-
sociation functional class III and had ischemic cardio-
myopathy . Although study of patients with milder symptoms
would have allowed prolongedhemodynamic monitoring in
the supine position, it has been demonstrated (32) that pa-
tients with more severe congestive heart failure show a
greater hemodynamic improvement after 10 mg of oral mil-
rinone.
In patients with evidence of reduced myocardial blood
supply. measurements of coronary hemodynamicsand myo-
cardial energetics after administration of a drug with va-
sodilating and inotropic effects are critical for the evaluation
of the drug. A possible deleterious role of milrinone in
patients with myocardial ischemia has to be mentioned .
because we observed that. in I of our 10 patients with
ischemic cardiomyopathy, a negative balance in myocardial
hypoxanthine occurred 50 minutes after milrinone intake.
The baseline pharmacologic therapy of each patient may
have exerted some effect. despite withdrawal , thereby in-
fluencing the measurements made during the study. We
believe that such limitations are common to the majority of
pharmacologic studies carried out in patients with severe
heart failure . We were aware of this potential limitation
when designing our protocol, but we believe it would have
been too dangerous to stop baseline pharmacologic therapy
earlier.
Conclusions. Oral milrinone improves left ventricular
relaxation and fill ing and reduces the abnormally high filling
pressure of the failing heart. This latter beneficial effect is
related to decreased preload and, less evidently, to an effect
on the intrinsic mechanical properties of myocardium reg-
ulating the diastolic pressure-volume relation.
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